These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 29690908)

  • 1. Adenosine deaminase deficiency: a review.
    Flinn AM; Gennery AR
    Orphanet J Rare Dis; 2018 Apr; 13(1):65. PubMed ID: 29690908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
    Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
    Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).
    Kohn DB; Gaspar HB
    J Clin Immunol; 2017 May; 37(4):351-356. PubMed ID: 28194615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency.
    Kohn DB; Hershfield MS; Puck JM; Aiuti A; Blincoe A; Gaspar HB; Notarangelo LD; Grunebaum E
    J Allergy Clin Immunol; 2019 Mar; 143(3):852-863. PubMed ID: 30194989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.
    Scott O; Kim VH; Reid B; Pham-Huy A; Atkinson AR; Aiuti A; Grunebaum E
    J Clin Immunol; 2017 Aug; 37(6):582-591. PubMed ID: 28748310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Cicalese MP; Ferrua F; Castagnaro L; Pajno R; Barzaghi F; Giannelli S; Dionisio F; Brigida I; Bonopane M; Casiraghi M; Tabucchi A; Carlucci F; Grunebaum E; Adeli M; Bredius RG; Puck JM; Stepensky P; Tezcan I; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Ciceri F; Roncarolo MG; Aiuti A
    Blood; 2016 Jul; 128(1):45-54. PubMed ID: 27129325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
    Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
    Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated Management Guidelines for Adenosine Deaminase Deficiency.
    Grunebaum E; Booth C; Cuvelier GDE; Loves R; Aiuti A; Kohn DB
    J Allergy Clin Immunol Pract; 2023 Jun; 11(6):1665-1675. PubMed ID: 36736952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
    Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
    Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
    J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omenn Syndrome can Occur during Enzyme Therapy for Adenosine Deaminase Deficiency.
    Forbes EM; McNaughton PB
    J Clin Immunol; 2024 Jul; 44(7):162. PubMed ID: 39008132
    [No Abstract]   [Full Text] [Related]  

  • 13. National experience with adenosine deaminase deficiency related SCID in Polish children.
    Dąbrowska-Leonik N; Piątosa B; Słomińska E; Bohynikova N; Bernat-Sitarz K; Bernatowska E; Wolska-Kuśnierz B; Kałwak K; Kołtan S; Dąbrowska A; Goździk J; Ussowicz M; Pac M
    Front Immunol; 2022; 13():1058623. PubMed ID: 36685585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
    Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
    J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.
    Cicalese MP; Ferrua F; Castagnaro L; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Roncarolo MG; Aiuti A
    Mol Ther; 2018 Mar; 26(3):917-931. PubMed ID: 29433935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for ADA-SCID, the first marketing approval of an
    Aiuti A; Roncarolo MG; Naldini L
    EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
    Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
    Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency.
    Van Eyck L; Hershfield MS; Pombal D; Kelly SJ; Ganson NJ; Moens L; Frans G; Schaballie H; De Hertogh G; Dooley J; Bossuyt X; Wouters C; Liston A; Meyts I
    J Allergy Clin Immunol; 2015 Jan; 135(1):283-7.e5. PubMed ID: 25457153
    [No Abstract]   [Full Text] [Related]  

  • 19. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.
    Ferrua F; Brigida I; Aiuti A
    Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):551-6. PubMed ID: 20966749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow transplantation and alternatives for adenosine deaminase deficiency.
    Gaspar HB
    Immunol Allergy Clin North Am; 2010 May; 30(2):221-36. PubMed ID: 20493398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.